Famvir®
famciclovir · oral tablet
Antiviral
Approved uses
Recurrent herpes labialis and recurrent genital herpes (treatment and chronic suppression) in immunocompetent adults, and recurrent orolabial or genital herpes in HIV-infected adults
Herpes labialis 1500 mg as a single dose. Recurrent genital herpes 1000 mg twice daily for 1 day. Chronic suppression 250 mg twice daily. HIV-infected adults 500 mg twice daily for 7 days.
OFF-LABELNot in the FDA label for this product
Herpes zoster ophthalmicus
500 mg three times daily for 7 days.
RCT · n=454 · vs acyclovir
Randomized, double-masked, acyclovir-controlled parallel-group multicenter trial across 87 centers, 454 patients with V1 ophthalmic zoster in the intent-to-treat population. One or more ocular manifestations occurred in 142 of 245 (58.0%) on famciclovir 500 mg three times daily versus 114 of 196 (58.2%) on acyclovir 800 mg five times daily, odds ratio 0.99 (95% CI 0.68 to 1.45), with no significant difference in severe or non-severe manifestations, in the prevalence of individual ocular manifestations, or in visual acuity loss. The comparator was acyclovir, not placebo, so the trial establishes similar efficacy rather than a treatment effect size. Timing is the actionable variable: a review of herpes zoster antivirals states that acyclovir, valacyclovir and famciclovir started within 72 hours of acute rash onset significantly shorten acute pain, viral shedding, rash, and acute and late-onset anterior segment complications, and that valacyclovir and famciclovir also reduce the incidence and severity of postherpetic neuralgia, but that none of these agents prevents it.
Contraindications
Known hypersensitivity to the product, its components, or penciclovir cream.
125 mg, 250 mg, 500 mg tablets; 500 mg in bottles of 21, 30, 60, 90; 21 tablets = 7 days at 500 mg three times daily (zoster trial)
Famciclovir is an orally administered prodrug of the antiviral agent penciclovir. In cells infected with HSV-1 or HSV-2, the viral thymidine kinase phosphorylates penciclovir to a monophosphate form that cellular kinases convert to the active form, penciclovir triphosphate. Penciclovir triphosphate inhibits HSV-2 DNA polymerase competitively with deoxyguanosine triphosphate, so herpes viral DNA synthesis and replication are selectively inhibited.
Warnings & Precautions
- Acute renal failure: Reported in patients with underlying renal disease who received doses inappropriately high for their level of renal function; reduce the dose in renal impairment.
- Unestablished efficacy and safety: The efficacy and safety of famciclovir tablets have not been established for patients <18 years of age, patients with first episode of genital herpes, immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in HIV-infected patients, and Black and African American patients with recurrent genital herpes.
- Delayed treatment start: The efficacy of famciclovir tablets when initiated more than 6 hours after onset of symptoms or lesions of recurrent genital herpes in immunocompetent adults, or more than 48 hours after onset of symptoms or lesions of recurrent orolabial or genital herpes in HIV-infected adults, has not been established.
- Suppression beyond 1 year: The efficacy and safety of famciclovir tablets for the suppression of recurrent genital herpes beyond 1 year have not been established.
- Resistance and cross-resistance: Penciclovir-resistant mutants of HSV can result from mutations in the viral thymidine kinase (TK) and DNA polymerase genes, and the most commonly encountered acyclovir resistant mutants that are TK negative are also resistant to penciclovir. Consider the possibility of viral resistance to penciclovir in patients who fail to respond or experience recurrent viral shedding during therapy.
- Penciclovir toxicity: Concurrent use with probenecid or other drugs eliminated largely by active renal tubular secretion may result in increased plasma concentrations of penciclovir. Monitor for evidence of penciclovir toxicity.
- Decreased penciclovir formation: Raloxifene, a potent aldehyde oxidase inhibitor in vitro, could decrease the formation of penciclovir. A clinical drug-drug interaction study of penciclovir and raloxifene has not been conducted.
Common Side Effects
The most common adverse events reported in at least 1 indication by >10% of adult patients treated with famciclovir are headache and nausea. Headache occurred in 13.5% versus 5.4% on placebo in recurrent genital herpes, 39.3% versus 42.9% in genital herpes suppression, and 8.5% versus 6.7% in herpes labialis. Nausea occurred in 2.5% versus 3.6%, 7.2% versus 9.5%, and 2.2% versus 3.9%, and diarrhea in 4.9% versus 1.2%, 9.0% versus 9.5%, and 1.6% versus 0.8%, respectively. In HIV-infected patients on 500 mg twice daily, headache occurred in 17%, nausea in 11%, diarrhea in 7%, vomiting in 5%, fatigue in 4%, and abdominal pain in 3%. Postmarketing reports include thrombocytopenia, cholestatic jaundice, anaphylactic shock, seizure, confusion, hallucinations, Stevens-Johnson syndrome, toxic epidermal necrolysis, and angioedema (e.g., face, eyelid, periorbital, and pharyngeal edema).
Pregnancy: Category B. No adequate and well-controlled studies in pregnant women. No adverse embryo-fetal effects were seen in rats or rabbits at oral doses providing up to 10.8 times (rats) and 5.4 times (rabbits) human systemic exposure by AUC. Use during pregnancy only if needed.
Lactation: Not known whether famciclovir or penciclovir are excreted in human milk; after oral dosing of lactating rats, penciclovir was excreted in milk at concentrations higher than in plasma. There are no infant safety data, so do not use in nursing mothers unless the potential benefits outweigh the potential risks.
Efficacy is not established in patients under 18 years of age, and the drug is not recommended in infants.